Free Trial

Protagonist Therapeutics (PTGX) Earnings Date, Estimates & Call Transcripts

Protagonist Therapeutics logo
$41.11 +0.07 (+0.17%)
(As of 11/15/2024 08:54 PM ET)

Skip Charts & View Estimated and Actual Earnings Data

PTGX Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

PTGX Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Protagonist Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20241$3.75$3.75$3.75
Q2 20241-$0.64-$0.64-$0.64
Q3 20242-$0.64-$0.53-$0.59
Q4 20242-$0.55-$0.41-$0.48
FY 20246$1.92$2.17$2.05
Q1 20252-$0.61-$0.61-$0.61
Q2 20252-$0.63-$0.11-$0.37
Q3 20252-$0.65-$0.53-$0.59
Q4 20252-$0.67$0.87$0.10
FY 20258($2.56)($0.38)($1.47)

Protagonist Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks
2/25/2025
(Estimated)
------- 
8/6/2024--$0.50-$0.50--$0.50$40.00M$4.17M  
5/7/2024Q1 2024$2.51$3.26+$0.75$3.26$300.00M$254.95M  
2/27/2024Q4 2023$0.05$0.44+$0.39$0.44$60.00M$60.00M  
11/2/2023Q3 2023-$0.68-$0.58+$0.10-$0.58--  
8/3/2023Q2 2023-$0.65-$0.68 -$0.03-$0.68--  
5/4/2023Q1 2023-$0.69-$0.67+$0.02-$0.67--  
The Harvard Business School proved his stock picking system works (Ad)

If you missed our last email, I hope you see this one. You see, this Tuesday afternoon we’re sitting down with the #1 ranked stock picker in North America. A man who’s beat out 16,000 stock market professionals on Sum Zero to claim the top spot… He was amongst the first to recommend many of today’s most dominant companies, including both Apple and Nvidia. And for the first time on a large scale, he’s going to share the stock rating system that made it all possible… Not only has this system been proven to generate significant alpha by The Harvard Business School… It also earned a patent from the US government… The technology behind this system is out of this world, and our #1 stock picker has agreed to let us test a number of stocks against it.

Follow this link here we’ll add you to the guest list.
3/15/2023Q4 2022-$0.67-$0.69 -$0.02-$0.69--  

Protagonist Therapeutics Earnings - Frequently Asked Questions

Protagonist Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 25th, 2025 based off last year's report dates. Learn more on PTGX's earnings history.

Protagonist Therapeutics (NASDAQ:PTGX) has a recorded annual revenue of $60 million.

Protagonist Therapeutics (NASDAQ:PTGX) has a recorded net income of -$78.96 million. PTGX has generated $2.66 earnings per share over the last four quarters.

Protagonist Therapeutics (NASDAQ:PTGX) has a trailing price-to-earnings ratio of 15.45 and a forward price-to-earnings ratio of 18.03.

Protagonist Therapeutics's earnings are expected to decrease from $2.28 per share to ($1.81) per share in the next year.

`

More Earnings Resources from MarketBeat



This page (NASDAQ:PTGX) was last updated on 11/18/2024 by MarketBeat.com Staff
From Our Partners